Rheumatology

Autoinflammatory disorders

Questions discussed in this category

What are your preferred alternative biologic agents for Blau Syndrome when anti-TNFα therapies are contraindicated?

Do you always pursue testing for NOD2 mutations when you are suspecting a diagnosis of Blau syndrome?

How would you approach diagnosis of a patient with recurrent episodes of abdominal pain, severe myalgias, low grade fevers and urticaria?

Does this presentation fall within the autoinflammatory spectrum, and is it consistent with FMF or would you consider another cytokine-driven process?...

4 Answers available

Which other agent would you consider for a patient with VEXAS who has failed methotrexate, multiple TNF inhibitors, Tocilizumab, and Ruxolitinib?

1 Answer available

Do you recommend genetic screening for FMF in asymptomatic first-degree relatives with a strong family history (multiple family members, severe/refractory disease)?

1 Answer available

How do you utilize cytokine panels in your clinical practice?

Is there utility when classic inflammatory markers (ESR,CRP) or disease specific markers (C3, C4, dsDNA) do not correlate with patients disease activi...

1 Answer available

What is your approach to evaluation and management of a patient with Blau Syndrome and GI manifestations?

2 Answers available

How do you approach management of Adult Onset Still's disease in a patient with ongoing fatigue and inflammatory joint pain despite methotrexate, colchicine, canakinumab and tocilizumab?

Heritable autoinflammatory gene testing negative. Is there a role for TNF inhibitor?

3 Answers available

How do you decide when to obtain genetic testing for suspected autoinflammatory conditions in adults?

2 Answers available

How do you approach management of a patient with persistent EBV infection and MAS despite treatment with Rituximab, anakinra and canakinumab?

Would you consider alternative B cell depleting therapies such as ofatumumab or ocrelizumab?

1 Answer available

Do you recommend using IL-1/IL-6 inhibitors in COVID-19 multisystem inflammatory syndrome in adults (MIS-A)?